Phase III MISSION trial of sorafenib monotherapy in heavily pretreated patients with non-small cell lung cancer
EGFR status may help select patients who will benefit most
Clever drugs for clever cancers
Pancreatic cancer is notoriously difficult to treat and is still associated with a dismal prognosis, despite decades of research.
COG study: Addressing the need for second-line treatments in oesophageal cancer
Phase III, randomised, double-blind, placebo-controlled trial of gefitinib versus placebo in oesophageal cancer progressing after chemotherapy
Four ongoing, early stage trials evaluate novel agents in NSCLC patients with ALK-positive and EGFR mutated tumours
Four new pharmacological interventions show promise in crizotinib naive patients or in overcoming resistance to ALK and tyrosine kinase inhibitors
Combining S-1 and docetaxel improves survival in advanced gastric cancer
Updated results of phase III START trial presented at ESMO 2012
New ‘first-in-man’ data to be presented at ESMO
This year’s ESMO Congress will provide us with a first glimpse at some new drugs that may eventually become cancer treatments in the future.
Young Oncologists: Master Class in Trial Design
ESMO’s Young Oncologist Programme began on Friday afternoon with a master class exploring the development of clinical trial protocols.The presenters reviewed issues around trial design in the era of targeted agents and biomarkers.
Promising new data from trials aimed to delay resistance to BRAF inhibitors
BRAF and MEK drug combinations reveal more understanding in acquired resistance to melanoma treatment